Sinocelltech Group Ltd
SSE:688520
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
31.32
56
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sinocelltech Group Ltd
Sinocelltech Group Ltd
Capital Expenditures
Sinocelltech Group Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sinocelltech Group Ltd
SSE:688520
|
Capital Expenditures
-¥505.4m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Capital Expenditures
-¥4.1B
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Capital Expenditures
-¥879.5m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Capital Expenditures
-¥1.2B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Capital Expenditures
-¥497.9m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-20%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Capital Expenditures
-¥1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-15%
|
|
Sinocelltech Group Ltd
Glance View
Sinocelltech Group Ltd. engages in the research and development, and manufacture of biopharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 1,353 full-time employees. The company went IPO on 2020-06-22. The firm focuses on monoclonal antibodies, recombinant proteins and vaccine products. Its main products are SCT800, SCT200, SCT-I10A, SCT400, SCT510, SCT1000 and SCT630, among others. The firm is also engaged in asset leasing business and payment collection business.
See Also
What is Sinocelltech Group Ltd's Capital Expenditures?
Capital Expenditures
-505.4m
CNY
Based on the financial report for Dec 31, 2023, Sinocelltech Group Ltd's Capital Expenditures amounts to -505.4m CNY.
What is Sinocelltech Group Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-38%
Over the last year, the Capital Expenditures growth was 9%. The average annual Capital Expenditures growth rates for Sinocelltech Group Ltd have been -63% over the past three years , -38% over the past five years .
You don't have any saved screeners yet
